This Article Full Text Full Text (PDF) All Versions of this Article: 92/6/2197    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Azim, A. A. Articles by Oktay, K. Search for Related Content PubMed PubMed Citation Articles by Azim, A. A. Articles by Oktay, K. Related Collections Female Endocrinology

Relative Potencies of Anastrozole and Letrozole to Suppress Estradiol in Breast Cancer Patients Undergoing Ovarian Stimulation before in Vitro Fertilization

Department of Obstetrics and Gynecology, Weill Medical College of Cornell University, New York, New York 10021

Address all correspondence to: Kutluk Oktay, M.D., FACOG, 505 East 70th Street, HT340, New York, New York 10021. E-mail: koktay{at}fertilitypreservation.org. Address requests for reprints to: Kutluk Oktay, Center for Reproductive Medicine, Infertility, Weill Medical College of Cornell University, New York, New York 10021.

Context: Breast cancer patients undergoing controlled ovarian hyperstimulation (COH) for embryo or oocyte cryopreservation should be induced by the method that leads to the least increase in estradiol (E₂) levels.

Objective: The aim of the study was to determine the potency of anastrozole to suppress serum E₂ levels in breast cancer patients undergoing COH.

Design and Setting: A prospective sequential cohort study was conducted in an academic center for reproductive medicine between May 2003 and November 2005 for letrozole and between December 2005 and April 2006 for anastrozole.

Patients: Breast cancer patients presenting for fertility preservation participated in the study.

Intervention: COH using FSH and letrozole (n = 47) or anastrozole (n = 7) was followed by oocyte retrieval and embryo cryopreservation.

Main Outcome Measures: Serum E₂ levels, area under the curve for E₂, and outcomes of COH cycles were measured.

Results: There were no significant differences between the two groups regarding length of stimulation, total gonadotropin dose, number of follicles larger than 17 mm, and the lead follicle size on human chorionic gonadotropin (hCG) day and number of embryos cryopreserved. The mean E₂ levels on the day of hCG and post-hCG days were higher in the anastrozole group compared to the letrozole group (1325.89 ± 833.17 and 2515.07 ± 1368.52 vs. 427.78 ± 278.24 and 714.38 ± 440.83 pg·d/ml; P 0.01), respectively, even when anastrozole dose was increased up to 10 mg/d. The mean area under the curve was significantly higher in the anastrozole group compared to the letrozole group (4402.93 ± 1526.7 vs. 1287.48 ± 732.17 pg·d/ml; P <0.004).

Conclusions: Breast cancer patients who underwent ovarian stimulation with anastrozole had a significantly higher exposure to E₂ than those who were stimulated with letrozole.

This article has been cited by other articles:

				J. Mieszczak, E. S. Lowe, P. Plourde, and E. A. Eugster The Aromatase Inhibitor Anastrozole Is Ineffective in the Treatment of Precocious Puberty in Girls with McCune-Albright Syndrome J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2751 - 2754. [Abstract] [Full Text] [PDF]

				A. A. Azim, M. Costantini-Ferrando, and K. Oktay Safety of Fertility Preservation by Ovarian Stimulation With Letrozole and Gonadotropins in Patients With Breast Cancer: A Prospective Controlled Study J. Clin. Oncol., June 1, 2008; 26(16): 2630 - 2635. [Abstract] [Full Text] [PDF]

				L. R. Schover Premature Ovarian Failure and Its Consequences: Vasomotor Symptoms, Sexuality, and Fertility J. Clin. Oncol., February 10, 2008; 26(5): 753 - 758. [Abstract] [Full Text] [PDF]